These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 36763086)

  • 1. Transcription Factor ELF1 Modulates Cisplatin Sensitivity in Prostate Cancer by Targeting MEIS Homeobox 2.
    Han D; Li X; Cheng Y
    Chem Res Toxicol; 2023 Mar; 36(3):360-368. PubMed ID: 36763086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
    Bhanvadia RR; VanOpstall C; Brechka H; Barashi NS; Gillard M; McAuley EM; Vasquez JM; Paner G; Chan WC; Andrade J; De Marzo AM; Han M; Szmulewitz RZ; Vander Griend DJ
    Clin Cancer Res; 2018 Aug; 24(15):3668-3680. PubMed ID: 29716922
    [No Abstract]   [Full Text] [Related]  

  • 4. CircDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.
    Dai X; Chen X; Chen W; Ou Y; Chen Y; Wu S; Zhou Q; Yang C; Zhang L; Jiang H
    Epigenetics; 2023 Dec; 18(1):2178802. PubMed ID: 36840946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
    Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
    J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.
    Chen JL; Li J; Kiriluk KJ; Rosen AM; Paner GP; Antic T; Lussier YA; Vander Griend DJ
    Clin Cancer Res; 2012 Aug; 18(16):4291-302. PubMed ID: 22723371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meis homeobox 2 (MEIS2) inhibits the proliferation and promotes apoptosis of thyroid cancer cell and through the NF-κB signaling pathway.
    Wen X; Liu M; Du J; Wang X
    Bioengineered; 2021 Dec; 12(1):1766-1772. PubMed ID: 33975520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation.
    Alshalalfa M; Abou-Ouf H; Davicioni E; Karnes RJ; Alhajj R; Bismar TA
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2223-2231. PubMed ID: 33864110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-128 modulates chemosensitivity and invasion of prostate cancer cells through targeting ZEB1.
    Sun X; Li Y; Yu J; Pei H; Luo P; Zhang J
    Jpn J Clin Oncol; 2015 May; 45(5):474-82. PubMed ID: 25921099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERN1 dependent impact of glucose and glutamine deprivations on PBX3, PBXIP1, PAX6, MEIS1, and MEIS2 genes expression in U87 glioma cells.
    Krasnytska DO; Viletska YM; Minchenko DO; Khita OO; Tsymbal DO; Cherednychenko AA; Kozynkevych HE; Oksiom NS; Minchenko OH
    Endocr Regul; 2023 Jan; 57(1):37-47. PubMed ID: 36753664
    [No Abstract]   [Full Text] [Related]  

  • 12. MEIS2 suppresses breast cancer development by downregulating IL10.
    Xiao Y; Liu Y; Sun Y; Huang C; Zhong S
    Cancer Rep (Hoboken); 2024 May; 7(5):e2064. PubMed ID: 38711262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2019 Apr; 10(4):324. PubMed ID: 30975979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
    Johng D; Torga G; Ewing CM; Jin K; Norris JD; McDonnell DP; Isaacs WB
    Prostate; 2019 Mar; 79(4):414-424. PubMed ID: 30560549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
    Jeong JH; Park SJ; Dickinson SI; Luo JL
    Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEIS2 promotes cell migration and invasion in colorectal cancer.
    Wan Z; Chai R; Yuan H; Chen B; Dong Q; Zheng B; Mou X; Pan W; Tu Y; Yang Q; Tu S; Hu X
    Oncol Rep; 2019 Jul; 42(1):213-223. PubMed ID: 31115559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEIS and PBX homeobox proteins in ovarian cancer.
    Crijns AP; de Graeff P; Geerts D; Ten Hoor KA; Hollema H; van der Sluis T; Hofstra RM; de Bock GH; de Jong S; van der Zee AG; de Vries EG
    Eur J Cancer; 2007 Nov; 43(17):2495-505. PubMed ID: 17949970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meis2 is a Pax6 co-factor in neurogenesis and dopaminergic periglomerular fate specification in the adult olfactory bulb.
    Agoston Z; Heine P; Brill MS; Grebbin BM; Hau AC; Kallenborn-Gerhardt W; Schramm J; Götz M; Schulte D
    Development; 2014 Jan; 141(1):28-38. PubMed ID: 24284204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative transcriptional activation by Klf4, Meis2, and Pbx1.
    Bjerke GA; Hyman-Walsh C; Wotton D
    Mol Cell Biol; 2011 Sep; 31(18):3723-33. PubMed ID: 21746878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
    Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
    BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.